半导体芯闻·2026-01-13 10:21Core Viewpoint - The article discusses the ongoing disputes faced by Wentech Technology (600745.SH) regarding its semiconductor and integrated business operations, particularly focusing on the arbitration case with Luxshare Precision's subsidiary over the Indian asset package transaction [1][2]. Group 1: Dispute Details - Wentech Technology's subsidiary in India has completed the transfer of its business assets, but a dispute has arisen with Luxshare's subsidiary regarding the payment of the remaining transaction price of approximately 160 million yuan [1]. - Luxshare has requested the arbitration court to terminate the "Indian Asset Agreement" and return the payment of approximately 1.977 billion Indian Rupees already made for the asset package [1][2]. - Wentech Technology is actively pursuing legal action to compel Luxshare to fulfill the contract and pay the remaining transaction price, while also seeking compensation for losses incurred [2]. Group 2: Business Transition - Wentech Technology's main business previously included integrated product and semiconductor operations, with the integrated business facing significant losses prior to the sale due to being placed on the U.S. Entity List [3]. - The company plans to sell its integrated business assets for 4.389 billion yuan, which includes 100% equity stakes in several subsidiaries and the Indian asset package [3][4]. - The revenue from the integrated business has drastically declined from 15.73 billion yuan in Q3 2024 to 110 million yuan in Q3 2025, with net profit primarily derived from the asset sale [5]. Group 3: Semiconductor Business Challenges - Wentech Technology's semiconductor business, primarily acquired through a 30 billion yuan investment in Nexperia, is facing significant operational uncertainties due to asset freezes imposed by Dutch authorities [5][6]. - The Dutch court has implemented emergency measures affecting Wentech's control over Nexperia, including the suspension of key management roles and the management of shares by a third party [5][6]. - The company has indicated that if control over Nexperia is not restored by the end of 2025, it may face risks related to revenue, profit, and cash flow [6].